Express Scripts Projects Higher Spending In Inflammation, Diabetes, Cancer
Executive Summary
The three most expensive drug categories, on a per-member/per-year basis for the PBM's clients, increased by 19% or more in 2016, and similar growth is expected in the next three years. Per-patient spending on HCV drugs, however, declined by 34% last year.
You may also be interested in...
Lilly's Basaglar, Crestor Generics Helped Hold Down Drug Spending Growth In 2017
Express Scripts' annual drug trend report highlights impact of key follow-on launches, and its own management solutions programs, in limiting the growth in overall drug spending for commercial plans to 1.5%; forecast calls for double-digit growth in inflammatory category to continue at least the next three years until biosimilar savings kick in.
Lilly's Basaglar, Crestor Generics Helped Hold Down Drug Spending Growth In 2017
Express Scripts' annual drug trend report highlights impact of key follow-on launches, and its own management solutions programs, in limiting the growth in overall drug spending for commercial plans to 1.5%; forecast calls for double-digit growth in inflammatory category to continue at least the next three years until biosimilar savings kick in.
Express Scripts Adds Gilead’s Harvoni To 2017 Formularies
The pharmacy benefit manager says it has been able to negotiate a discount with Gilead enabling it to give both Harvoni and AbbVie’s Viekira Pak preferred formulary placement. Express Scripts also is expanding its indication-based oncology management initiative.